Double radiation attack on resistant prostate cancer shows promise in early trial
NCT ID NCT04886986
First seen Apr 10, 2026 · Last updated May 12, 2026 · Updated 6 times
Summary
This early-phase study tests a new combination of two drugs that deliver radiation directly to prostate cancer cells. The goal is to find the safest dose for men with advanced prostate cancer that has stopped responding to hormone therapy. About 20 participants will receive both drugs together to see how well they tolerate the treatment and whether it lowers PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brooklyn Methodist Hospital - New York Presbyterian
Brooklyn, New York, 11215, United States
-
Weill Cornell Medicine New York Presbyterian
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.